Last reviewed 2026-05-19 · How we verify

90Y-DOTA-3-Tyr-Octreotide

David Bushnell · Phase 1 active Small molecule ✓ Verified May 2026 Quality 15/100

90Y-DOTA-3-Tyr-Octreotide is a Small molecule drug developed by David Bushnell. It is currently in Phase 1 development. Also known as: 90Y DOTATOC.

90Y-DOTA-3-Tyr-Octreotide is a peptide used in peptide receptor radionuclide therapy for various conditions, including pancreatic neuroendocrine tumors, neuroendocrine tumors, meningioma, neuroblastoma, and medulloblastoma. It is a protein modality that targets specific receptors.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	90Y-DOTA-3-Tyr-Octreotide
Also known as	90Y DOTATOC
Sponsor	David Bushnell
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Nausea
Vomiting
Fatigue
Abdominal pain
Headache
Anemia
Dizziness
Fever
Infusion site extravasation
Lymphocyte count decreased
Endocrine disorders - Other, specify
Platelet count decreased

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

90Y-DOTA-3-Tyr-Octreotide CI brief — competitive landscape report
90Y-DOTA-3-Tyr-Octreotide updates RSS · CI watch RSS
David Bushnell portfolio CI

Frequently asked questions about 90Y-DOTA-3-Tyr-Octreotide

What is 90Y-DOTA-3-Tyr-Octreotide?

90Y-DOTA-3-Tyr-Octreotide is a Small molecule drug developed by David Bushnell.

Who makes 90Y-DOTA-3-Tyr-Octreotide?

90Y-DOTA-3-Tyr-Octreotide is developed by David Bushnell (see full David Bushnell pipeline at /company/david-bushnell).

Is 90Y-DOTA-3-Tyr-Octreotide also known as anything else?

90Y-DOTA-3-Tyr-Octreotide is also known as 90Y DOTATOC.

What development phase is 90Y-DOTA-3-Tyr-Octreotide in?

90Y-DOTA-3-Tyr-Octreotide is in Phase 1.

What are the side effects of 90Y-DOTA-3-Tyr-Octreotide?

Common side effects of 90Y-DOTA-3-Tyr-Octreotide include Nausea, Vomiting, Fatigue, Abdominal pain, Headache, Anemia.

Manufacturer: David Bushnell — full pipeline
Also known as: 90Y DOTATOC

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing